Novel guanosine derivatives as anti-HCV NS5b polymerase: A QSAR and molecular docking study

Medicinal Chemistry

Volumn 15, Issue 2, 2019, Pages 130-137

  Elfiky, Abdo A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Guanosine inhibitors; Hepatitis c virus (HCV); NS5b polymerase; Protein ligand docking; QSAR; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; GUANOSINE DERIVATIVE; IDX 184; NONSTRUCTURAL PROTEIN 5B; SOFOSBUVIR; GUANOSINE; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HEPATITIS C VIRUS; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HEPACIVIRUS; METABOLISM; PROTEIN CONFORMATION;

ANTIVIRAL AGENTS; GUANOSINE; HEPACIVIRUS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85062083382     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/1573406414666181015152511     Document Type: Article

References (33)

1. Halfon, P.; Locarnini, S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol., 2011, 55(1), 192-206.
2. Genovese, D.; Dettori, S.; Argentini, C.; Villano, U.; Chionne, P.; Angelico, M.; Rapicetta, M. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J. Clin. Microbiol., 2005, 43(4), 1902-1909.
3. Bahgat, M.M.; Ibrahim, A.A.; Abd-Elshafy, D.N.; Mesalam, A. A.; Gewaid, H.E.; Ismaeil, A.A.; El-Waseef, A.M.; Maghraby, A.S.; Barakat, A.B.; El-Far, M.A.; Ghanem Hel, D.; Mohamed, A.M.; Ali, M.A. Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate. Arch. Virol., 2009, 154(10), 1649-1657.
4. Yang, P.L.; Gao, M.; Lin, K.; Liu, Q.; Villareal, V.A. Anti-HCV drugs in the pipeline. Curr. Opin. Virol., 2011, 1(6), 607-616.
5. Das, D.; Hong, J.; Chen, S.H.; Wang, G.; Beigelman, L.; Seiwert, S.D.; Buckman, B.O. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorg. Med. Chem., 2011, 19(16), 4690-703.
6. De Francesco, R.; Carfí, A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev., 2007, 59(12), 1242-1262.
7. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiv. Res., 2003, 58(1), 1-16.
8. Gonzalez-Grande, R.; Jimenez-Perez, M.; Gonzalez Arjona, C.; Mostazo Torres, J. New approaches in the treatment of hepatitis C. World J. Gastroenterol., 2016, 22(4), 1421-1432.
9. Asselah, T. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J. Hepatol., 2014, 61(2), 435-8.
10. Lemon, S.M.; McKeating, J.A.; Pietschmann, T.; Frick, D.N.; Glenn, J.S.; Tellinghuisen, T.L.; Symons, J.; Furman, P.A. Development of novel therapies for hepatitis C. Antiv. Res., 2010, 86(1), 79-92.
11. Sarrazin, C.; Hézode, C.; Zeuzem, S.; Pawlotsky, J.-M. Antiviral strategies in hepatitis C virus infection. J. Hepatol., 2012, 56, S88-S100.
12. Yan, S.; Appleby, T.; Larson, G.; Wu, J.Z.; Hamatake, R.; Hong, Z.; Yao, N. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(22), 5888-5891.
13. Yan, S.; Larson, G.; Wu, J.Z.; Appleby, T.; Ding, Y.; Hamatake, R.; Hong, Z.; Yao, N. Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure. Bioorg. Med. Chem. Lett., 2007, 17(1), 63-67.
14. Graham, D.J.; Stahlhut, M.; Flores, O.; Olsen, D.B.; Hazuda, D. J.; LaFemina, R.L.; Ludmerer, S.W. A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background. Antiv. Res., 2006, 69(1), 24-30.
15. Elfiky, A.A.; Elshemey, W.M. IDX-184 is a superior HCV directacting antiviral drug: a QSAR study. Med. Chem. Res., 2016, 25, 1005-1008.
16. Elfiky, A.A.; Elshemey, W.M.; Gawad, W. A. 2′-Methylguanosine Prodrug (IDX-184), Phosphoramidate Prodrug (Sofosbuvir), Diisobutyryl Prodrug (R7128) Are Better Than Their Parent Nucleotides and Ribavirin in Hepatitis C Virus Inhibition: A Molecular Modeling Study. J. Comput. Theor. Nanosci., 2015, 12(3), 376-386.
17. Elfiky, A.A. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J. Med. Virol., 2016, 88, 2044-2051.
18. Saleh, N.A.; Elfiky, A.A.; Ezat, A.A.; Elshemey, W.M.; Ibrahim, M. The Electronic and quantitative structure activity relationship properties of modified telaprevir compounds as hcv ns3 protease inhibitors. J. Computa. Theore. Nanosci., 2014, 11(2), 544-548.
19. Saleh, N.A.; Ezat, A.A.; Elfiky, A.A.; Elshemey, W.M.; Ibrahim, M. Theoretical study on modified boceprevir compounds as ns3 protease inhibitors. J. Computat.Theoret. Nanosci., 2015, 12(3), 371-375.
20. Raj, V.S.; Osterhaus, A.D.; Fouchier, R.A.; Haagmans, B.L. MERS: Emergence of a novel human coronavirus. Curr. Opin. Virol., 2014, 5, 58-62.
21. Elfiky, A.A.; Elshemey, W.M.; Gawad, W.A.; Desoky, O.S. Molecular modeling comparison of the performance of NS5b polym erase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J., 2013, 32(1), 75-80.
22. Schmitz, C.; Bonvin, A.M. Protein-protein HADDocking using exclusively pseudocontact shifts. J. Biomol NMR, 2011, 50(3), 263-6.
23. Zhou, X. J.; Pietropaolo, K.; Chen, J.; Khan, S.; Sullivan-Bolyai, J.; Mayers, D. Safety and pharmacokinetics of IDX184, a livertargeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob. Agents Chemother., 2011, 55(1), 76-81.
24. Licia Tomei, S.A. Giacomo Paonessa, Raffaele De Francesco and Giovanni Migliaccio, HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antiv. Chem. Chemother., 2005, 16, 225-245.
25. Saleh, N.A. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors. Spectrochim Acta A Mol. Biomol. Spectrosc., 2014, 136PC, 1523-1529.
26. Elfiky, A.A.; Gawad, W.A.; Elshemey, W.M. Hepatitis C Viral Polymerase Inhibition using Directly Acting Antivirals, A Computational Approach. In Software and Techniques for Bio-Molecular Modeling, A, M., Ed. Austin publishing group: USA, In press.
27. Summers, K.L.; Mahrok, A.K.; Dryden, M.D.; Stillman, M.J. Structural properties of metal-free apometallothioneins. Biochem Biophys. Res. Commun., 2012, 425(2), 485-92.
28. O’Farrell, D.; Trowbridge, R.; Rowlands, D.; Jäger, J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): Structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol., 2003, 326(4), 1025-1035.
29. Harrus, D.; Ahmed-El-Sayed, N.; Simister, P.C.; Miller, S.; Triconnet, M.; Hagedorn, C.H.; Mahias, K.; Rey, F.A.; Astier-Gin, T.; Bressanelli, S. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem., 2010, 285(43), 32906-18.
30. Cretton-Scott, E.; Perigaud, C.; Peyrottes, S.; Licklider, L.; Camire, M.; Larsson, M.; La Colla, M.; Hildebrand, E.; Lallos, L.; Bilello, J. 588 in vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. HepatoL., 2008, 48, S220.
31. Stedman, C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therapeut. Advan. Gastroenterol., 2014, 7(3), 131-140.
32. Naka, K.; Ikeda, M.; Abe, K.-i.; Dansako, H.; Kato, N. Mizoribine inhibits hepatitis C virus RNA. Biophys. Res. Commun., 2005, 330(3), 871-879.
33. Harrus, D.; Ahmed-El-Sayed, N.; Simister, P.C.; Miller, S.; Triconnet, M.; Hagedorn, C.H.; Mahias, K.; Rey, F.A.; Astier-Gin, T.; Bressanelli, S. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem., 2010, 285(43), 32906-32918.